About
Capabilities
DEL for

DEL for Unconventional Applications
DEL for Kinases
DEL for Covalent Ligand Discovery
DNA-Encoded Library (DEL) for Compound Optimization & Expansion
DEL for Enzymes with Specific Mode of Action (MoA)
DEL for Protein-Protein Interaction
DEL for RNA
DEL for DNA- and RNA-Binding Proteins
DEL for GPCRs
DEL for Protein Degradation

DNA-encoded Library

DNA-encoded Library Design
DNA-encoded Library Synthesis
DNA-encoded Library Screening
DNA-encoded Library Application
DNA-compatible Chemistry Development
DEL Oligo Design and Synthesis
OpenDEL^®
DEL _EZ™

Fragment-based Drug Discovery

Protein Engineering, Expression and Purification
X-Ray Crystallography
Fragment Screening
Biophysical Assay
Biochemical Assay
FBDD Case Study

Chemistry

Synthetic Chemistry
Parallel Synthesis
Medicinal Chemistry
Analytical Chemistry
Nucleoside Chemistry
Oligonucleotide Chemistry
Process Chemistry

Bioscience

Protein Engineering, Expression and Purification
Biochemical Assay
Biophysical Assay
Cellular Assay
Protein Degradation Assay
ASMS for Feature Compound Identification
2nd Gen DNA Sequencing

Computational Sciences and Informatics

Target Nomination and Analysis
Virtual Screening
Structure-based Drug Design
Ligand-based Drug Design
AI-based Scaffold Hopping
ADMET Prediction
Chemoinformatics
Bioinformatics

Structural Biology

Protein production
X-Ray crystallography
Structure analysis

Pre-clinical Studies

Pharmacodynamics
PK/PD Study
DMPK
Non-GLP Repeated-dose Toxicology
Toxicokinetics
AMES

Clinical Development

Clinical Science and Medical Affairs
Clinical Operation
Services
Target Validation

Protein Science
Target Knockdown by siRNA
CRISPR

Hit Identification

DNA-encoded Library
Fragment-based Drug Discovery
Virtual Screening
Nucleic Acid Related Chemistry
Analytical Chemistry

Hit-to-Lead Optimization

Hit Expansion by DEL
Structure-based Drug Design
Parallel Synthesis
Biochemical Assay
Biophysical Assay
Cellular Assay
ADME Prediction
DMPK

Lead Optimization

Medicinal Chemistry
Computational Science
AI-based Drug Design
Project DEL
Scale-up Capability
In Vitro Toxicity
In Vitro Pharmacology
In Vivo Pharmacology
Pharmacokinetics
Non-GLP Toxicity

Preclinical Studies and IND

Process Chemistry
Formulation
Analytical Development and Quality Control
Pharmacology
DMPK
Project Management
Regulatory Affairs

Clinical Development

Clinical Science and Medical Affairs
Clinical Operation

Integrated Drug Discovery

One-Stop Small Molecule Drug Discovery
Targeted Protein Degradation Platform
Nucleic Acid Drug Discovery
Therapeutic Areas
Pipeline
News
Investors
Careers

Investors

688222

RMB

Highest
Lowest
Volume
Amount

Up to Beijing time. There is 15-minute delay in the quoted price.

Announcements

Interim Announcement

Annual Report

Investors
Annual Report

成都先导药物开发股份有限公司2020年年度业绩快报公告 Release Time：2021-02-27

The Board Office is in charge of the information disclosure and investor relations. The secretary of the board is Shiwei Geng.

Tel:

+86 28 85197385

E-mail:

investors@hitgen.com

info@hitgen.com

Sites: HitGen Inc.

Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China

Tel : +86-28-8519-7385

HitGen Pharmaceuticals Inc.(US Subsidiary)

Tel : +1-(508)-840-9646

Vernalis (R&D) Limited (UK Subsidiary)

Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom

Tel : +44(0)1223-895555

Contact: Business Inquiry : bd@hitgen.com; Investor Relations : investors@hitgen.com; Media : media@hitgen.com; Career and Jobs : human.resources@hitgen.com

We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for More information

↑